Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 in Cognitive Impairment Due to Alzheimer's Disease
NCT02337907Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of osoresnontrine in Alzheimer's disease (AD), sponsored by Boehringer Ingelheim. Started Jan 2015; status: completed.
02
Drugs
osoresnontrine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02337907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337907.